AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04275960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
Study NCT01892176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme q10
Description: 400mg/day, 800mg/day, 1200/day and 2400mg/day
Study NCT01744340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colon- Closed as of May 2014
Description: Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Study NCT00492115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
Study NCT00492115 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CPAP
Description: Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
Study NCT00840528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: 0.4 ppm ozone for 2 hours
Study NCT01706744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate care unit
Study NCT01706744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local health care 1
Study NCT03831347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 12 weeks of Hatha Yoga
Study NCT02278588 — intervention group
Intervention type: DRUG
Intervention: Rasagiline
Study NCT01706744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local health care 2
Study NCT01440829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Description: The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
Study NCT02603939 — intervention group
Intervention type: PROCEDURE
Intervention: Joint replacement surgery
Description: We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
Study NCT02411877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Device: Trevo Pro Retriever (Stryker Corp.)
Study NCT02411877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
Study NCT02411877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trevo Pro Retriever (Stryker Corp.)
Description: Device: Trevo Pro Retriever (Stryker Corp.)
Study NCT02411877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo Pro Retriever (Stryker Corp.)
Description: Device: Trevo Pro Retriever (Stryker Corp.)
Study NCT04615663 — intervention group
Intervention type: BEHAVIORAL
Intervention: Score SMI
Description: the investigator will complete the SMI score
Study NCT04321148 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care PCI
Description: optimal medical care PCI
Study NCT04321148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impella-protected PCI
Description: Impella-protected PCI
Study NCT02677987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention systematic light exposure
Description: Bright light using Litebook device.
Study NCT02677987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison systematic light exposure
Description: Dim light using modified Litebook device.
Study NCT02411877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll Thermogard XP technology with the Quattro catheter
Description: Device: Zoll Thermogard XP technology with the Quattro catheter
Study NCT01318291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCRI Group
Description: Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
Study NCT01064401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: Daclizumab High Yield Process for subcutaneous injection
Study NCT01064401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a Placebo
Description: Placebo to interferon beta-1a intramuscular injection
Study NCT01064401 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a for intramuscular injection
Study NCT01064401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab High Yield Process Placebo
Description: Placebo to Daclizumab High Yield Process subcutaneous injection
Study NCT00763308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Heart Healthy Program
Description: The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
Study NCT02738151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300U/mL
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
Study NCT02738151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec, 100 U/mL
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous
Study NCT02738151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-insulin anti-diabetic treatment
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Study NCT02738151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-insulin anti-diabetic treatment
Description: Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Study NCT04247360 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cuff pressure
Description: maintaining cuff pressure according the groups
Study NCT01318291 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Medical treatment alone
Study NCT02894294 — intervention group
Intervention type: OTHER
Intervention: implementation of seasonal malaria chemoprevention
Description: administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
Study NCT01112189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
Study NCT01112189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compressed sleeve treatment
Description: Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment
Study NCT04296721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive weigh-loss program
Description: Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
Study NCT04296721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary recommendations
Description: Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
Study NCT00685828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: By mouth
Study NCT00685828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: By mouth
Study NCT01296230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hormone and semen measurements before varicocelectomy
Description: Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
Study NCT02074475 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
Study NCT01914510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Study NCT04722692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Delayed SLND
Description: SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer.
Study NCT04722692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Late SLND
Description: SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer.
Study NCT00537810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: 15 mg daily
Study NCT00537810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily
Study NCT00537810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT + Sibutramine
Description: Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
Study NCT00537810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT + Placebo
Description: Cognitive behavioral treatment manual for binge eating Placebo daily
Study NCT04520256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Behavioral Weight Loss Skills Training
Description: This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
Study NCT02434250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
Study NCT01913015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study NCT01913015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive low fat breakfast
Study NCT01913015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Receive high fat breakfast
Study NCT03196869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy
Description: Chrono-chemotherapy+concurrent radiochemotherapy
Study NCT03196869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip
Description: Routine intravenous drip-chemotherap
Study NCT03196869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction Chrono-chemotherapy
Description: Experimental group:docetaxel,cisplatin,5-FU
Study NCT03196869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: induction Routine-chemotherapy
Description: control group:docetaxel,cisplatin,5-FU
Study NCT01913015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01913015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01913015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02542566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy rehabilitation
Description: Physiotherapy rehabilitation
Study NCT05008302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
Study NCT01278810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
Study NCT03196869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy
Description: Experimental group: cisplatin chrono-chemotherapy
Study NCT02701569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Repeated jumping on a mini trampoline was administered
Study NCT02109939 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: GeneSight Psychotropic
Description: The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented.
Study NCT02109939 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: GeneSight Psychotropic
Description: The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented.
Study NCT03823963 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mepilex® Border dressing
Description: Soft silicone self-adherent dressing (5-layers)
Study NCT03823963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The control group will receive pressure ulcer prevention standard care
Study NCT03823963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The control group will receive pressure ulcer prevention standard care
Study NCT03441399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Providing money for taking antidepressant medication
Study NCT02237573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written medical report and standardized medical advices
Description: The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients.
Study NCT02237573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator.
Study NCT05385172 — intervention group
Intervention type: OTHER
Intervention: No any intervation.
Description: This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
Study NCT04316780 — intervention group
Intervention type: OTHER
Intervention: Retrospective observational study- no intervention to occur.
Description: Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
Study NCT03196869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy
Description: control group:cisplatin routine-chemotherapy
Study NCT03196869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: control group is similar to Experimental group
Study NCT03196869 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Description: control group is similar to Experimental group
Study NCT00245635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
Study NCT00245635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
Study NCT04972890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
Study NCT04715789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graded exposure and activity
Description: 1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner
Study NCT02163720 — intervention group
Intervention type: DRUG
Intervention: Yondelis®-Caelyx®
Description: Observation of Yondelis®-Caelyx® administration
Study NCT04972890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: using 2 cc saline/NaCl 0,9% solution
Study NCT01041586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTVA System
Description: Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction